Evidence map›Paper›PMID 22615829›Full record

ArticlePloS one2012

Comparing HLA shared epitopes in French Caucasian patients with scleroderma.

Doua F Azzouz, Justyna M Rak, Isabelle Fajardy, Yannick Allanore, Kiet Phong Tiev, Dominique Farge-Bancel, Marielle Martin, Sami B Kanaan, Philippe P Pagni, Eric Hachulla and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Pathogenesis of Systemic Sclerosis.Frontiers in immunology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Doua F AzzouzLaboratoire d'Immunogénétique de la Polyarthrite Rhumatoïde, INSERM UMRs1097, Marseille, France.
Justyna M Rak
Isabelle Fajardy
Yannick Allanore
Kiet Phong Tiev
Dominique Farge-Bancel
Marielle Martin
Sami B Kanaan
Philippe P Pagni
Eric Hachulla
Jean Robert Harlé
Rémi Didelot
Brigitte Granel
Jean Cabane
Jean Roudier
Nathalie C Lambert
Inserm · FRHôpital Claude Huriez · FRHôpital Cochin · FRHôpital de la Conception · FRHôpital Nord · FRHôpital Saint-Louis · FRl'Assurance Maladie · FRSorbonne Université · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although many studies have analyzed HLA allele frequencies in several ethnic groups in patients with scleroderma (SSc), none has been done in French Caucasian patients and none has evaluated which one of the common amino acid sequences, (67)FLEDR(71), shared by HLA-DRB susceptibility alleles, or (71)TRAELDT(77), shared by HLA-DQB1 susceptibility alleles in SSc, was the most important to develop the disease. HLA-DRB and DQB typing was performed for a total of 468 healthy controls and 282 patients with SSc allowing FLEDR and TRAELDT analyses. Results were stratified according to patient's clinical subtypes and autoantibody status. Moreover, standardized HLA-DRß1 and DRß5 reverse transcriptase Taqman PCR assays were developed to quantify ß1 and ß5 mRNA in 20 subjects with HLA-DRB1*15 and/or DRB1*11 haplotypes. FLEDR motif is highly associated with diffuse SSc (χ(2) = 28.4, p<10-6) and with anti-topoisomerase antibody (ATA) production (χ(2) = 43.9, p<10-9) whereas TRAELDT association is weaker in both subgroups (χ(2) = 7.2, p = 0.027 and χ(2) = 14.6, p = 0.0007 respectively). Moreover, FLEDR motif- association among patients with diffuse SSc remains significant only in ATA subgroup. The risk to develop ATA positive SSc is higher with double dose FLEDR than single dose with respectively, adjusted standardised residuals of 5.1 and 2.6. The increase in FLEDR motif is mostly due to the higher frequency of HLA-DRB1*11 and DRB1*15 haplotypes. Furthermore, FLEDR is always carried by the most abundantly expressed ß chain: ß1 in HLA DRB1*11 haplotypes and ß5 in HLA-DRB1*15 haplotypes.In French Caucasian patients with SSc, FLEDR is the main presenting motif influencing ATA production in dcSSc. These results open a new field of potential therapeutic applications to interact with the FLEDR peptide binding groove and prevent ATA production, a hallmark of severity in SSc.

Indexed as

AllelesEpitopesFemaleGene FrequencyGenetic Predisposition to DiseaseHaplotypesHLA AntigensHLA-DQ beta-ChainsHLA-DRB1 ChainsHLA-DRB5 ChainsHumansLinkage DisequilibriumMaleMiddle AgedRNA, MessengerScleroderma, SystemicEpitopesHLA AntigensHLA-DQB1 antigenHLA-DQ beta-ChainsHLA-DRB1 ChainsHLA-DRB5 ChainsRNA, Messenger

Identifiers

PMID22615829
PMCPMC3352938
OpenAlexW1974759626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.